Form 4 for INDV Indivior Pharmaceuticals, Inc.

Accepted 2026-02-12 00:00:00 ET · period of report 2026-02-09 · accession 0002014866-26-000004 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-02-12	2026-02-10	INDV	Preblick Ryan	CFO	A - Grant	$0.00	+37.4K	317.9K	+13%	$0
D	2026-02-12	2026-02-09	INDV	Preblick Ryan	CFO	A - Grant	$0.00	+113.5K	113.5K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-02-10	A	A	37,358	$0.00	317,940	D	—	—	(F1) Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer.
2	Derivative	Performance Stock Units	2026-02-09	A	A	113,510	$0.00	113,510	D	$0.00 · 2028-03-03 to —	113,510 Common Stock	(F2) On March 3, 2023, the Reporting Person was granted a conditional award for 113,510 shares, subject to satisfaction of performance conditions, which were certified on February 9, 2026. The award vests, subject to continued employment conditions, on March 3, 2026. The shares will then be subject to an additional two-year Holding Period before the vested Shares are released to the Reporting Person.